Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Marker Therapeutics
About
Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
- Minneapolis,Minnesota,United States
- 51 - 100
- https://www.markertherapeutics.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 1992
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:MRKR
- Legal Name
- Marker Therapeutics, Inc.
Marker Therapeutics is a clinical stage immuno-oncology company focused on developing adoptive non-gene modified T cell therapies for the treatment of hematologic malignancies such as Acute Myeloid Leukemia, Lymphoma, and Multiple Myeloma. Marker’s MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Marker’s therapies is significantly reduced.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 13, 2022 | Post-IPO Equity | $25M | 1 |
Lincoln Park Capital Fund
|
— | Detail |
| Sep 13, 2022 | Grant | $2M | 1 |
U.S. Food and Drug Administration
|
— | Detail |
| Aug 19, 2021 | Grant | $13.10M | 1 |
Cancer Prevention and Research Institute of Texas
|
— | Detail |
| Mar 12, 2021 | Post-IPO Equity | $56.50M | — | — | — | Detail |
| Jun 5, 1998 | IPO | — | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Lincoln Park Capital Fund
|
Yes | Post-IPO Equity |
|
U.S. Food and Drug Administration
|
Yes | Grant |
|
Cancer Prevention and Research Institute of Texas
|
Yes | Grant |
